US-based investment bank Goldman Sachs has reaffirmed its neutral rating for General Electric (GE) spin-off company, GE HealthCare Technologies. The decision follows GE's strategic move to separate its health division into an independent entity.
The neutral rating indicates that analysts at Goldman Sachs believe the stock price of GE HealthCare is fairly valued and may not experience significant growth or decline in the short term. Analysts expect moderate expansion in the medical equipment sector, driven by increasing demand for healthcare services.
GE's health division has been a significant contributor to the company's revenue, with its 2022 sales reaching USD $18.7 billion. The separation of the unit is expected to create new opportunities for both GE and GE HealthCare Technologies in the growing medical technology market.
The move by Goldman Sachs underscores its assessment that GE HealthCare will continue to perform steadily but does not provide significant upside potential. However, investors remain optimistic about the future prospects of the company due to the ongoing growth in healthcare spending worldwide.